Chronic fluoxetine or desmethylimipramine treatment alters 5-HT2 receptor mediated c-fos gene expression

These studies examined the effects of a 21-day treatment regime with either the tricyclic antidepressant, desmethylimipramine (DMI), or the selective 5-HT uptake inhibitor, fluoxetine, on 5-HT2 receptors in rat brain, as assessed by selective agonist-mediated c-fos gene expression. Chronic, but not...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 1995-08, Vol.290 (3), p.263-266
Main Authors: TILAKARATNE, N, ZHELIN YANG, FRIEDMAN, E
Format: Article
Language:English
Subjects:
Amphetamines - pharmacology
Animals
Antidepressive Agents, Tricyclic - pharmacology
Biological and medical sciences
Cerebral Cortex - drug effects
Cerebral Cortex - metabolism
Desipramine - pharmacology
Fluoxetine - pharmacology
Gene Expression - drug effects
Genes, fos - drug effects
Hippocampus - drug effects
Hippocampus - metabolism
Ketanserin - pharmacology
Male
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Rats
Rats, Sprague-Dawley
Receptors, Serotonin - drug effects
Receptors, Serotonin - metabolism
RNA - biosynthesis
RNA - metabolism
Serotonin Antagonists - pharmacology
Serotonin Receptor Agonists - pharmacology
Serotonin Uptake Inhibitors - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:These studies examined the effects of a 21-day treatment regime with either the tricyclic antidepressant, desmethylimipramine (DMI), or the selective 5-HT uptake inhibitor, fluoxetine, on 5-HT2 receptors in rat brain, as assessed by selective agonist-mediated c-fos gene expression. Chronic, but not acute, treatment with fluoxetine (10 mg/kg, i.p. for 21 days) resulted in supersensitization of the response to an acute challenge (4 mg/kg, i.p.) with the selective 5-HT2 agonist, 2,5-dimethoxy-4-iodoamphetamine (DOI), both in frontal cortex and in hippocampus. Chronic treatment with DMI (10 mg/kg, i.p. for 21 days) resulted in a significant desensitization of the response to DOI. These findings are discussed in relation to the possible modes of action of these two clinically useful agents.
ISSN:0922-4106
0014-2999
1879-0712
DOI:10.1016/0922-4106(95)90003-9